TRIM27 Antibody

What is TRIM27 and what cellular functions has it been associated with?

TRIM27, also known as RFP (Ret Finger Protein), is a member of the TRIM/RBCC protein family characterized by a conserved RING domain with E3 ubiquitin ligase activity. TRIM27 has been identified as a transcriptional repressor that cooperates with EPC1 and has DNA-binding activity with preference for double-stranded DNA . It plays significant roles in:

• Cell proliferation and cell cycle regulation through G0-G1/S phase transition

• Apoptosis induction by activating JNK and p38 kinase pathways

• Immune response modulation, particularly through affecting CD4+ T cell activation

• Male germ cell development and spermatogenesis

The protein has a calculated molecular weight of 58 kDa but can also be observed at 41 kDa in some experimental systems .

What validated applications exist for TRIM27 antibodies in research?

Based on the available data, TRIM27 antibodies have been validated for multiple applications:

It is important to note that proper antibody titration is recommended in each experimental system to achieve optimal results .

How should TRIM27 antibodies be stored to maintain optimal activity?

TRIM27 antibodies should be stored at -20°C according to manufacturer specifications. Most commercial antibodies are stable for one year after shipment under these conditions . The formulation typically includes:

• PBS with 0.02% sodium azide

• 50% glycerol at pH 7.3

Aliquoting is generally unnecessary for -20°C storage, and some preparations may contain 0.1% BSA as a stabilizer . It's important to avoid repeated freeze-thaw cycles to maintain antibody performance.

What are the optimal methods for studying TRIM27-mediated protein ubiquitination?

When investigating TRIM27's E3 ubiquitin ligase activity, researchers should consider:

• Co-immunoprecipitation with ubiquitination analysis: This approach has been successfully used to demonstrate that TRIM27 can ubiquitinate proteins like p21 and LKB1 . The experimental workflow should include:

  • Treatment with proteasome inhibitors (e.g., MG132) to prevent degradation of ubiquitinated proteins

  • Immunoprecipitation of the target protein

  • Western blot analysis using anti-ubiquitin antibodies

• In vitro ubiquitination assays: These can help confirm direct ubiquitination by TRIM27. This requires:

  • Purified recombinant TRIM27 protein

  • E1 and E2 enzymes

  • Ubiquitin

  • Potential substrate proteins

• Site-directed mutagenesis: Creating RING domain mutants of TRIM27 can help establish the specificity of the ubiquitination activity. The experimental evidence shows that TRIM27's RING domain is essential for its E3 ligase activity and interaction with targets such as LKB1 in glioblastoma cells .

In the case of p21, researchers have shown that TRIM27 overexpression enhanced p21 ubiquitination in T47D cells, and MG132 treatment rescued p21 protein levels, confirming that TRIM27 mediates p21 degradation through the ubiquitin-proteasome pathway .

What controls should be included when studying TRIM27 in cancer progression models?

Based on published research on TRIM27's role in cancer progression, the following controls are essential:

• Expression validation controls:

  • Positive control tissues: Jurkat cells, Raji cells for WB applications

  • Human lung cancer tissue and mouse testis tissue for IHC applications

  • HepG2 and HeLa cells for IF/ICC applications

• Knockdown/overexpression controls:

  • When performing TRIM27 knockdown, use multiple siRNA/shRNA constructs to rule out off-target effects

  • For overexpression studies, include empty vector controls and monitor for any cytotoxic effects from the overexpression system itself

• Functional validation:

  • For proliferation studies: Include both short-term (CCK-8/EdU) and long-term (colony formation) assays as demonstrated in studies with TRIM27 in colorectal cancer and glioblastoma models

  • For apoptosis/senescence: Include analysis of multiple markers (e.g., cleaved caspase-3, β-galactosidase) rather than relying on a single readout

  • For EMT studies: Monitor multiple markers (E-cadherin, N-cadherin, vimentin) as done in colorectal cancer studies

• In vivo models:

  • Use both subcutaneous tumor xenograft models to assess tumor growth and metastasis models (e.g., tail vein injection) to evaluate invasion capabilities

  • Include immunohistochemical analysis of proliferation markers (Ki67) in harvested tumors

What methodologies are recommended for investigating TRIM27 interactions with signaling pathways?

To investigate TRIM27's interactions with signaling pathways, researchers have successfully employed:

• Co-immunoprecipitation (CoIP):

  • This technique has been used to identify novel TRIM27-interacting proteins, such as p21 in breast cancer and LKB1 in glioblastoma

  • Example protocol: Perform immunoprecipitation with anti-TRIM27 antibody followed by Western blot analysis for the suspected interacting protein, or vice versa

• Proteomics approaches:

  • Liquid chromatography/mass spectrometry (LC/MS) has been effective in identifying candidate proteins associated with TRIM27

  • This approach revealed p21 as a TRIM27-interacting protein in breast cancer cells

• Pathway analysis:

  • For immune-related functions: Gene set enrichment analysis (GSEA), ESTIMATE, CIBERSORT, and gene set variation analysis (GSVA) have been used to correlate TRIM27 expression with immune cell infiltration patterns

  • For metabolic pathways: Analysis of the LKB1/AMPK/mTOR axis in relation to TRIM27 expression revealed its role in promoting the Warburg effect in glioblastoma

• Combined knockdown/overexpression studies:

  • Studies have shown that simultaneous knockdown of p21 and TRIM27 or their simultaneous overexpression can help determine whether TRIM27's effects are mediated through specific signaling molecules

  • This approach confirmed that p21 is a key mediator of TRIM27's oncogenic functions in breast cancer cells

How can I differentiate between TRIM27's roles in different cancer types?

TRIM27 exhibits context-dependent functions across cancer types. To differentiate its roles:

• Comparative expression analysis:

  • TRIM27 is upregulated in non-triple-negative breast cancer (non-TNBC) , colorectal cancer , and glioblastoma

  • In right-sided colon cancer, high TRIM27 expression correlates with poor prognosis, hypermetabolism, and lower CD4+ T cell infiltration

• Pathway-specific investigations:

  • In breast cancer: Focus on TRIM27's interaction with p21 and its effects on cell cycle regulation and TAM resistance

  • In colorectal cancer: Investigate EMT markers and AKT activation (phosphorylated AKT)

  • In glioblastoma: Study the LKB1/AMPK/mTOR axis and the Warburg effect

  • In right-sided colon cancer: Examine immune infiltration patterns, particularly CD4+ T cells, and the mTORC1/glycolysis pathway

• Clinical correlation studies:

  • Use Kaplan-Meier survival analysis to assess the prognostic value of TRIM27 in specific cancer types

  • In right-sided colon cancer, univariate Cox regression analysis has identified TRIM27 as a gene significantly affecting prognosis

• Unique mechanisms in different cancers:

  • In colorectal cancer: TRIM27 promotes EMT by increasing N-cadherin and vimentin while decreasing E-cadherin

  • In breast cancer: TRIM27 contributes to tamoxifen resistance by inhibiting apoptosis and senescence

  • In immune contexts: TRIM27 negatively correlates with activated B cells, Type-1 T-helper cells, mast cells, and neutrophils

How can I investigate TRIM27's role in immune regulation experimentally?

To investigate TRIM27's role in immune regulation:

• Immune cell infiltration analysis:

  • Use techniques like CIBERSORT to estimate the relative proportion of 22 types of immune cells in relation to TRIM27 expression

  • Studies have shown that patients with low TRIM27 expression present higher stromal cell and immune cell infiltration, while those with high TRIM27 expression demonstrate higher tumor purity

• Co-culture experiments:

  • Design co-culture systems with cancer cells (manipulated for TRIM27 expression) and immune cells (particularly CD4+ T cells)

  • Measure T cell activation markers, proliferation, and cytokine production

• Specific immune cell subsets:

  • Focus on resting memory CD4+ T cells, plasma cells, and dendritic cells, which have been found to be fewer in number in patients with high TRIM27 expression

  • Also examine M0 and M1 macrophages, which are more abundant in patients with high TRIM27 expression

• Pathway inhibition studies:

  • Test whether inhibiting the mTORC1/glycolysis pathway can reverse TRIM27's effects on immune cell infiltration

  • Research has suggested that TRIM27 may function by activating the mTORC1/glycolysis pathway and suppressing CD4+ T cells

• Mycobacterial infection models:

  • TRIM27 has been identified as a host restriction factor that promotes innate immune responses and cell apoptosis in response to Mycobacterium tuberculosis infection

  • Design experiments to study how TRIM27 restricts mycobacterial survival in macrophages

What are the optimal methods for detecting differences in TRIM27 localization during cellular processes?

TRIM27 can localize to different cellular compartments, which may be critical for its functions. To study its localization:

• Subcellular fractionation combined with Western blotting:

  • Separate nuclear, cytoplasmic, and membrane fractions

  • Perform Western blot analysis using anti-TRIM27 antibodies

  • Include proper loading controls for each fraction (e.g., lamin for nuclear fraction, GAPDH for cytoplasmic fraction)

• Immunofluorescence with confocal microscopy:

  • Use validated antibodies for IF/ICC applications (e.g., in HepG2 and HeLa cells)

  • Recommended dilution: 1:200-1:800

  • Include co-staining with markers for specific cellular compartments (e.g., DAPI for nucleus, markers for PML bodies)

  • TRIM27 has been associated with PML bodies in the nucleus

• Live-cell imaging:

  • Generate fluorescently tagged TRIM27 constructs

  • Monitor localization changes in response to stimuli or during cell cycle progression

  • Validate findings with endogenous protein using fixed-cell immunofluorescence

• Co-localization studies:

  • Examine co-localization with interaction partners

  • For example, studying TRIM27 co-localization with p21 or LKB1 under different cellular conditions

How can I troubleshoot inconsistent TRIM27 detection in Western blots?

When experiencing inconsistent TRIM27 detection:

• Consider molecular weight variations:

  • TRIM27 has a calculated molecular weight of 58 kDa, but can also be observed at 41 kDa

  • This could represent different isoforms or post-translational modifications

• Optimize antibody dilution:

  • Recommended dilution range for Western blot is 1:1000-1:6000

  • Titrate the antibody to find the optimal concentration for your specific sample type

• Sample preparation considerations:

  • TRIM27 has been successfully detected in Jurkat cells, mouse testis tissue, and Raji cells

  • Ensure proper protein extraction methods are used for your specific sample type

• Loading controls and normalization:

  • Include appropriate loading controls

  • Consider normalizing TRIM27 expression to total protein rather than single housekeeping proteins

• Buffer and transfer optimization:

  • For IHC applications, antigen retrieval with TE buffer pH 9.0 is suggested, although citrate buffer pH 6.0 may also be used

  • For Western blot, follow the validated protocols provided by antibody manufacturers

How should I interpret differences in TRIM27 expression between normal and cancer tissues?

When analyzing TRIM27 expression differences:

• Context-specific interpretation:

  • TRIM27 is upregulated in multiple cancer types, including non-triple-negative breast cancer , colorectal cancer , and glioblastoma

  • High expression correlates with poor prognosis in right-sided colon cancer

• Correlation with clinical parameters:

  • Analyze TRIM27 expression in relation to tumor invasion, metastasis, and patient prognosis

  • In colorectal cancer, TRIM27 expression is significantly associated with these parameters

• Pathway activation assessment:

  • Examine associated pathways in parallel with TRIM27 expression

  • Check phosphorylated AKT levels in colorectal cancer

  • Investigate LKB1/AMPK/mTOR axis components in glioblastoma

  • Analyze mTORC1/glycolysis pathway activation in right-sided colon cancer

• Immune infiltration correlation:

  • High TRIM27 expression is associated with lower CD4+ T cell infiltration in some cancer types

  • Consider analyzing immune cell populations alongside TRIM27 expression

• Validation across multiple techniques:

  • Confirm expression differences using multiple approaches (RT-qPCR, Western blot, IHC)

  • The same approach has been used to validate TRIM27 upregulation in colorectal cancer tissues compared to adjacent normal tissues

What potential pitfalls should I consider when studying TRIM27 in animal models?

When using animal models to study TRIM27:

• Model selection considerations:

  • Nude mice have been successfully used for xenograft models with TRIM27-manipulated cancer cells

  • For subcutaneous xenograft models, both MCF-7 (with/without TRIM27 knockdown) and T47D cells (with/without TRIM27 overexpression) have been used

  • For metastasis studies, tail vein injection models with LoVo cells have demonstrated TRIM27's role in liver metastasis

• Endpoint measurements:

  • Standard measurements include tumor volume and weight

  • Additional analyses should include immunohistochemical assessment of proliferation markers like Ki67

  • For metastasis studies, hematoxylin and eosin staining of potential metastatic sites (e.g., liver) is recommended

• Validation across cell lines:

  • Use multiple cell lines to confirm findings

  • For instance, knockdown experiments in MCF-7 and BT-474 cells, with overexpression studies in T47D cells, have provided complementary evidence for TRIM27's role in breast cancer

• Temporal considerations:

  • For tumor growth, a 4-week period post-implantation has been successful in demonstrating differences between control and TRIM27-manipulated tumors

  • For metastasis studies, a longer timeframe (7 weeks post-injection) may be necessary to observe differences in liver metastasis

• Control groups:

  • Include proper controls for both knockdown and overexpression studies

  • Monitor for any adverse effects that might confound interpretation of results

What emerging areas of TRIM27 research hold promise for therapeutic development?

Several emerging areas show potential for therapeutic development:

• TRIM27 as a cancer biomarker:

  • TRIM27 has been identified as an adverse prognostic biomarker in right-sided colon cancer

  • Its high expression in glioblastoma correlates with poor patient outcomes

  • Further validation across cancer types could establish TRIM27 as a clinically useful biomarker

• Targeting TRIM27-protein interactions:

  • The interaction between Mycobacterium tuberculosis PtpA and TRIM27 represents a potential target for tuberculosis treatment

  • Disrupting TRIM27's interaction with p21 could have therapeutic potential in breast cancer

  • Interfering with TRIM27-LKB1 interaction might reverse the Warburg effect in glioblastoma

• Immunotherapy applications:

  • TRIM27's role in suppressing CD4+ T cell infiltration suggests it may impact immunotherapy efficacy

  • Combining TRIM27 inhibition with immune checkpoint blockade might enhance treatment outcomes

• Metabolic targeting:

  • TRIM27's involvement in the Warburg effect via the LKB1/AMPK/mTOR axis offers opportunities for metabolic-based interventions in glioblastoma

  • Combining TRIM27 inhibition with metabolic inhibitors could provide synergistic effects

• Chemoresistance modulation:

  • TRIM27 contributes to tamoxifen resistance in breast cancer cells

  • Targeting TRIM27 could potentially resensitize resistant tumors to established therapies

How might advances in protein degradation technologies be applied to TRIM27 research?

New protein degradation technologies could advance TRIM27 research:

• Proteolysis-targeting chimeras (PROTACs):

  • Given TRIM27's E3 ubiquitin ligase activity, PROTAC approaches could be developed to redirect its activity toward therapeutic targets

  • Alternatively, PROTACs could be designed to target TRIM27 itself for degradation in contexts where it promotes disease

• Molecular glues:

  • These compounds could be designed to disrupt specific TRIM27 protein-protein interactions

  • For example, disrupting TRIM27's interaction with p21 or LKB1 could have therapeutic potential

• Deubiquitinase inhibitors:

  • Identifying deubiquitinases that counteract TRIM27-mediated ubiquitination could provide new therapeutic targets

  • Inhibiting these enzymes might enhance TRIM27-dependent degradation of oncogenic proteins

• CRISPR-based approaches:

  • CRISPR screens could identify synthetic lethal interactions with TRIM27 in cancer cells

  • CRISPR-based gene editing could be used to create more precise animal models for studying TRIM27 function

• Targeted protein degradation in combination therapy:

  • Combining TRIM27-targeting degraders with existing therapies like tamoxifen in breast cancer or immune checkpoint inhibitors in cancers with immune involvement